Fiscal 2026 Revenue of $4.70 Billion, up 3.6% YoY as Reported and 3.0% YoY in Constant Currency(1)
Announces Eight-Year Strategic aOS Agreement with AT&T
Enters the Insurance Industry Through the Acquisition of EIS
Initiates Fiscal 2027 Guidance & Fiscal 2028 Expectations:
Fiscal 2027 Revenue Outlook of (17.9%)-(14.3%) YoY as Reported, and (11%)-(7%) in Pro Forma(2) Constant Currency(1)
Provides Fiscal 2028 Expectations for Mid-Single Digit Revenue Growth, High-Single Digit Earnings Growth & Steadily Rising Dividend
Full Year Fiscal 2026 Highlights
(All comparisons are against prior year, unless otherwise stated)
Fourth Quarter Fiscal 2026 Highlights
(All comparisons are against same quarter of the prior year, unless otherwise stated)
JERSEY CITY, NJ / ACCESS Newswire / November 3, 2026 / Amdocs Limited (NASDAQ:DOX) today reported operating results for the three months ended September 30, 2026.
"We delivered solid fourth quarter and full year fiscal 2026 results, consistent with our guidance, and I want to thank our employees around the world for their focus and commitment. I took over as CEO two quarters ago, and since then we have moved fast to develop a new growth strategy and are busy executing it. The core pillar of that strategy is aOS, our Agentic Operating System for telco, which is quickly gaining market traction. Today we announced a significant, eight-year strategic agreement with AT&T, our largest customer. It expands our longstanding partnership by pairing aOS with AT&T's AI-enabled delivery framework to modernize its business and customer operations. On top of AT&T, we are also excited to announce another three major strategic aOS deals with VodafoneThree in UK, VEON in Eurasia and Globe in Philippines. Together, these deals are great examples of how aOS is enabling Amdocs to expand its activities and becoming the trusted partner of choice for our customers' agentic journeys," said Shimie Hortig, president and chief executive officer of Amdocs Management Limited.
Hortig continued, "We are also excited to announce our entry into a new vertical with the acquisition of EIS, a leading provider of an agentic multi-line insurance platform. This is our first step into the insurance industry. It significantly expands our addressable market and establishes insurance as a strategic medium- to long-term growth engine for Amdocs. The rationale is compelling. Insurance shares many of the characteristics that have defined our success in telecommunications: highly regulated environments, complex and mission-critical platforms, and data-intensive workflows. EIS brings an AI-native core platform, an established global customer base, and deep knowledge of both Life & Annuities and Property & Casualty. By combining EIS' assets and deep vertical expertise, with Amdocs aOS, our scale and our accountability-driven business model, we aim to provide a differentiated offering and become their partner of choice to lead their agentic journey."
Hortig concluded, "We believe our growing strategic momentum, expansion into the insurance market and internal transformation will position us for long-term growth and improved profitability. As part of the focus of our new strategy, we also decided to exit certain businesses and activities that aren't strategically relevant to our agentic future, including the recently announced sale of our media business and the exit of non-strategic business activities relating to the resale of hardware activities. Looking into fiscal 2027, our guidance reflects major headwinds from T-Mobile due to a recent dispute, the completion of the integration project of the USCellular customers and reduction in T-Mobile's discretionary spending. That said, the rest of our business remains robust and continues showing growth in fiscal 2027. Moreover, with positive market traction for aOS and an expanding pipeline of significant customer opportunities, our fiscal 2028 expectations position us for mid-single digit revenue growth, high-single digit earnings growth and a steadily rising dividend."
Revenue
(All comparisons are against the prior year period)
| In millions | ||||||||||||||
| Three months ended | Twelve months ended | |||||||||||||
| September 30, 2026 | September 30, 2026 | |||||||||||||
| Actual | Previous Guidance | Actual | Previous Guidance | |||||||||||
Revenue | $ | 1,194 | $1,175-$1,215 | $ | 4,697 | - | ||||||||
Revenue Growth, as reported | 3.8 | % | - | 3.6 | % | 3.2%-4.0% | ||||||||
Revenue Growth, constant currency (1) | 4.0 | % | - | 3.0 | % | 2.6%-3.4% | ||||||||
Net Income and Earnings Per Share
| In thousands, except per share data | ||||||||||||||||
| Three months ended | Twelve months ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
GAAP Measures | ||||||||||||||||
Net Income | $ | 140,823 | $ | 97,114 | $ | 501,242 | $ | 567,769 | ||||||||
Net Income attributable to Amdocs Limited | $ | 139,871 | $ | 96,327 | $ | 497,421 | $ | 564,704 | ||||||||
Diluted earnings per share | $ | 1.35 | $ | 0.88 | $ | 4.68 | $ | 5.05 | ||||||||
Non-GAAP Measures | ||||||||||||||||
Non-GAAP Net Income | $ | 206,097 | $ | 202,203 | $ | 791,669 | $ | 784,267 | ||||||||
Non-GAAP Net Income attributable to Amdocs Limited | $ | 205,145 | $ | 201,416 | $ | 787,848 | $ | 781,202 | ||||||||
Non-GAAP Diluted earnings per share | $ | 1.98 | $ | 1.83 | $ | 7.41 | $ | 6.99 | ||||||||
Capital Allocation & Liquidity
Twelve-month Backlog
First Quarter Fiscal 2027 Outlook
| In millions | |||
| except per share data | |||
| Q1 2027 | |||
Revenue | $955-$995 | ||
GAAP Diluted earnings per share | $0.81-$0.89 | ||
Non-GAAP Diluted earnings per share | $1.27-$1.33 |
Full Year Fiscal 2027 Outlook
| Year-over-Year growth | ||||
| FY 2027 | ||||
Revenue Growth, as reported | (17.9%)-(14.3%) | |||
Revenue growth, pro forma(2) constant currency(1) | (11%)-(7%) | |||
GAAP Diluted earnings per share | (25%)-(17%) | |||
Non-GAAP Diluted earnings per share | (30%)-(26%) | |||
| In millions | ||||
| FY 2027 | ||||
Free Cash Flow (4) | $440-$500 | |||
The forward-looking statements regarding our first fiscal quarter 2027 and full year fiscal 2027 guidance take into consideration the Company's current expectations regarding macroeconomic, geopolitical and industry specific risks and various uncertainties and certain assumptions, some of which we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, changes to trade policies including tariffs and trade restrictions and the resulting impact on economic activities (as our outlook assumes current economic conditions do not deteriorate significantly due to trade policy or other macro factors) global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, including customer spending behavior which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. In particular, our guidance makes assumptions about our relationship with T-Mobile, and actual developments could vary materially, including due to the results of any potential proceeding or settlement thereof. See "Forward-Looking Statements" below.
Conference Call and Earnings Webcast Presentation Details
Amdocs will host a conference call and earnings webcast presentation on November 3, 2026 at 5:00 p.m. Eastern Time to discuss the Company's fourth quarter of fiscal 2026 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast.
Non-GAAP Financial Measures
This release includes non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(3), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:
Free cash flow(3) equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures.
Amdocs believes that the presentation of non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(2), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.
For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.
Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.
Supporting Resources
About Amdocs
Amdocs develops, transforms and operates the mission-critical systems that businesses depend on every day. With more than 40 years of experience serving the world's leading communications companies, we combine proprietary technology, deep industry expertise and end-to-end accountability, from transformation through ongoing operations and evolution. Powered by aOS, our agentic operating system, we bring industry-specific AI into core business processes, advancing customers toward intelligent, increasingly autonomous operations across business, IT and network domains. We enable customers to modernize complex systems in highly regulated environments while maintaining the reliability, security and scale their businesses demand, driving measurable improvements in customer experience, operational efficiency and revenue growth.
Amdocs runs billions of transactions daily, and our technology is relied on every day. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ: DOX) and reported revenue of $4.7 billion in fiscal 2026. For more information, visit www.amdocs.com.
Forward-Looking Statements
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' strategy, including with respect to artificial intelligence and agentic opportunities, growth, financial outlook, and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks, uncertainties, and other important factors that may cause future results to differ materially from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyber attacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, continued developments with T-Mobile including potential arbitration and loss of revenue from their contracts, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and our Form 6-K furnished for the first quarter of fiscal 2026 on February 17, 2026, for the second quarter of fiscal 2026 on May 26, 2026 and for the third quarter of fiscal 2026 on August 18, 2026.
Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: dox_info@amdocs.com
AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data)
| Three months ended September 30, | Fiscal year ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenue | $ | 1,193,769 | $ | 1,150,218 | $ | 4,696,582 | $ | 4,532,913 | ||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | 754,156 | 719,878 | 2,906,352 | 2,811,333 | ||||||||||||
Research and development | 80,114 | 87,865 | 335,460 | 340,845 | ||||||||||||
Selling, general and administrative | 123,872 | 121,807 | 540,522 | 506,108 | ||||||||||||
Amortization of purchased intangible assets and other | 21,412 | 14,287 | 77,828 | 62,424 | ||||||||||||
Restructuring charges | 25,346 | 73,756 | 153,476 | 80,539 | ||||||||||||
| 1,004,900 | 1,017,593 | 4,013,638 | 3,801,249 | |||||||||||||
Operating income | 188,869 | 132,625 | 682,944 | 731,664 | ||||||||||||
Interest and other expense, net | (15,867 | ) | (11,843 | ) | (47,177 | ) | (38,422 | ) | ||||||||
Income before income taxes | 173,002 | 120,782 | 635,767 | 693,242 | ||||||||||||
Income taxes | 32,179 | 23,668 | 134,525 | 125,473 | ||||||||||||
Net income | $ | 140,823 | $ | 97,114 | $ | 501,242 | $ | 567,769 | ||||||||
Net income attributable to noncontrolling interests | 952 | 787 | 3,821 | 3,065 | ||||||||||||
Net income attributable to Amdocs Limited | $ | 139,871 | $ | 96,327 | $ | 497,421 | $ | 564,704 | ||||||||
Basic earnings per share attributable to Amdocs Limited | $ | 1.35 | $ | 0.88 | $ | 4.69 | $ | 5.08 | ||||||||
Diluted earnings per share attributable to Amdocs Limited | $ | 1.35 | $ | 0.88 | $ | 4.68 | $ | 5.05 | ||||||||
Basic weighted average number of shares outstanding | 103,282 | 109,279 | 105,947 | 111,147 | ||||||||||||
Diluted weighted average number of shares outstanding | 103,494 | 109,853 | 106,288 | 111,746 | ||||||||||||
Cash dividends declared per share | $ | 0.569 | $ | 0.527 | $ | 2.234 | $ | 2.060 | ||||||||
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)
| Three months ended September 30, | Fiscal year ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Revenue | $ | 1,193,769 | $ | 1,150,218 | $ | 4,696,582 | $ | 4,532,913 | ||||||||
Non-GAAP operating income | 257,268 | 248,118 | 1,012,452 | 968,330 | ||||||||||||
Non-GAAP net income | 206,097 | 202,203 | 791,669 | 784,267 | ||||||||||||
Non-GAAP net income attributable to Amdocs Limited | 205,145 | 201,416 | 787,848 | 781,202 | ||||||||||||
Non-GAAP diluted earnings per share | $ | 1.98 | $ | 1.83 | $ | 7.41 | $ | 6.99 | ||||||||
Diluted weighted average number of shares outstanding | 103,494 | 109,853 | 106,288 | 111,746 | ||||||||||||
Free Cash Flows
(In thousands)
| Three months ended September 30, | Fiscal year ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
Net Cash Provided by Operating Activities | $ | 153,740 | $ | 229,840 | $ | 672,723 | $ | 749,096 | ||||||||
Purchases of property and equipment, net (a) | (31,759 | ) | (31,212 | ) | (110,528 | ) | (103,952 | ) | ||||||||
Free Cash Flow | $ | 121,981 | $ | 198,628 | $ | 562,195 | $ | 645,144 | ||||||||
(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment.
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
| Three Months Ended September 30, 2026 | |||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Restructuring charges | Other | Tax effect | Non-GAAP | ||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||
Cost of revenue | $ | 754,156 | $ | - | $ | (10,420 | ) | $ | (135 | ) | $ | - | $ | - | $ | - | $ | 743,601 | |||||||
Research and development | 80,114 | (1,919 | ) | 78,195 | |||||||||||||||||||||
Selling, general and administrative | 123,872 | (9,032 | ) | (135 | ) | 114,705 | |||||||||||||||||||
Amortization of purchased intangible assets and other | 21,412 | (21,412 | ) | - | |||||||||||||||||||||
Restructuring charges | 25,346 | (25,346 | ) | - | |||||||||||||||||||||
Total operating expenses | 1,004,900 | (21,412 | ) | (21,371 | ) | (270 | ) | (25,346 | ) | - | - | 936,501 | |||||||||||||
Operating income | 188,869 | 21,412 | 21,371 | 270 | 25,346 | 257,268 | |||||||||||||||||||
Interest and other expense, net | (15,867 | ) | 2,106 | (13,761 | ) | ||||||||||||||||||||
Income taxes | 32,179 | 5,231 | 37,410 | ||||||||||||||||||||||
Net income | 140,823 | 21,412 | 21,371 | 270 | 25,346 | 2,106 | (5,231 | ) | 206,097 | ||||||||||||||||
Net income attributable to noncontrolling interests | 952 | 952 | |||||||||||||||||||||||
Net income attributable to Amdocs Limited | $ | 139,871 | $ | 21,412 | $ | 21,371 | $ | 270 | $ | 25,346 | $ | 2,106 | $ | (5,231 | ) | $ | 205,145 | ||||||||
| Three Months Ended September 30, 2025 | |||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Restructuring charges | Other | Tax effect | Non-GAAP | ||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||
Cost of revenue | $ | 719,878 | $ | - | $ | (13,062 | ) | $ | (360 | ) | $ | - | $ | - | $ | - | $ | 706,456 | |||||||
Research and development | 87,865 | (2,600 | ) | 85,265 | |||||||||||||||||||||
Selling, general and administrative | 121,807 | (11,068 | ) | (360 | ) | 110,379 | |||||||||||||||||||
Amortization of purchased intangible assets and other | 14,287 | (14,287 | ) | - | |||||||||||||||||||||
Restructuring charges | 73,756 | (73,756 | ) | - | |||||||||||||||||||||
Total operating expenses | 1,017,593 | (14,287 | ) | (26,730 | ) | (720 | ) | (73,756 | ) | - | - | 902,100 | |||||||||||||
Operating income | 132,625 | 14,287 | 26,730 | 720 | 73,756 | 248,118 | |||||||||||||||||||
Interest and other expense, net | (11,843 | ) | 1,545 | (10,298 | ) | ||||||||||||||||||||
Income taxes | 23,668 | 11,949 | 35,617 | ||||||||||||||||||||||
Net income | 97,114 | 14,287 | 26,730 | 720 | 73,756 | 1,545 | (11,949 | ) | 202,203 | ||||||||||||||||
Net income attributable to noncontrolling interests | 787 | 787 | |||||||||||||||||||||||
Net income attributable to Amdocs Limited | $ | 96,327 | $ | 14,287 | $ | 26,730 | $ | 720 | $ | 73,756 | $ | 1,545 | $ | (11,949 | ) | $ | 201,416 | ||||||||
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
| Fiscal year ended September 30, 2026 | |||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Restructuring charges | Other | Tax effect | Non-GAAP | ||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||
Cost of revenue | $ | 2,906,352 | $ | - | $ | (43,191 | ) | $ | (763 | ) | $ | - | $ | - | $ | - | $ | 2,862,398 | |||||||
Research and development | 335,460 | (7,642 | ) | 327,818 | |||||||||||||||||||||
Selling, general and administrative | 540,522 | (54,230 | ) | 7,622 | 493,914 | ||||||||||||||||||||
Amortization of purchased intangible assets and other | 77,828 | (77,828 | ) | - | |||||||||||||||||||||
Restructuring charges | 153,476 | (153,476 | ) | - | |||||||||||||||||||||
Total operating expenses | 4,013,638 | (77,828 | ) | (105,063 | ) | 6,859 | (153,476 | ) | 3,684,130 | ||||||||||||||||
Operating income | 682,944 | 77,828 | 105,063 | (6,859 | ) | 153,476 | 1,012,452 | ||||||||||||||||||
Interest and other expense, net | (47,177 | ) | (4,069 | ) | (51,246 | ) | |||||||||||||||||||
Income taxes | 134,525 | 35,012 | 169,537 | ||||||||||||||||||||||
Net income | 501,242 | 77,828 | 105,063 | (6,859 | ) | 153,476 | (4,069 | ) | (35,012 | ) | 791,669 | ||||||||||||||
Net income attributable to noncontrolling interests | 3,821 | 3,821 | |||||||||||||||||||||||
Net income attributable to Amdocs Limited | $ | 497,421 | $ | 77,828 | $ | 105,063 | $ | (6,859 | ) | $ | 153,476 | $ | (4,069 | ) | $ | (35,012 | ) | $ | 787,848 | ||||||
| Fiscal year ended September 30, 2025 | |||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other | Equity based compensation expense | Changes in certain acquisitions related liabilities measured at fair value | Restructuring charges | Other | Tax effect | Non-GAAP | ||||||||||||||||||
Operating expenses: | |||||||||||||||||||||||||
Cost of revenue | $ | 2,811,333 | $ | - | $ | (51,320 | ) | $ | (1,081 | ) | $ | - | $ | - | $ | - | $ | 2,758,932 | |||||||
Research and development | 340,845 | (9,603 | ) | 331,242 | |||||||||||||||||||||
Selling, general and administrative | 506,108 | (43,941 | ) | 12,242 | 474,409 | ||||||||||||||||||||
Amortization of purchased intangible assets and other | 62,424 | (62,424 | ) | - | |||||||||||||||||||||
Restructuring charges | 80,539 | (80,539 | ) | - | |||||||||||||||||||||
Total operating expenses | 3,801,249 | (62,424 | ) | (104,864 | ) | 11,161 | (80,539 | ) | 3,564,583 | ||||||||||||||||
Operating income | 731,664 | 62,424 | 104,864 | (11,161 | ) | 80,539 | 968,330 | ||||||||||||||||||
Interest and other expense, net | (38,422 | ) | 7,524 | (30,898 | ) | ||||||||||||||||||||
Income taxes | 125,473 | 27,692 | 153,165 | ||||||||||||||||||||||
Net income | 567,769 | 62,424 | 104,864 | (11,161 | ) | 80,539 | 7,524 | (27,692 | ) | 784,267 | |||||||||||||||
Net income attributable to noncontrolling interests | 3,065 | 3,065 | |||||||||||||||||||||||
Net income attributable to Amdocs Limited | $ | 564,704 | $ | 62,424 | $ | 104,864 | $ | (11,161 | ) | $ | 80,539 | $ | 7,524 | $ | (27,692 | ) | $ | 781,202 | |||||||
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)
| As of | ||||||||
| September 30, 2026 | September 30, 2025 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 197,049 | $ | 324,999 | ||||
Accounts receivable, net, including unbilled | 1,091,475 | 935,751 | ||||||
Prepaid expenses and other current assets | 328,226 | 331,387 | ||||||
Total current assets | 1,616,750 | 1,592,137 | ||||||
Property and equipment, net | 734,051 | 768,557 | ||||||
Lease assets | 151,469 | 182,088 | ||||||
Goodwill and other intangible assets, net | 3,241,526 | 3,046,962 | ||||||
Other noncurrent assets | 654,841 | 660,086 | ||||||
Total assets | $ | 6,398,637 | $ | 6,249,830 | ||||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable, accruals and other | $ | 1,253,278 | $ | 1,201,206 | ||||
Short-term financing arrangements | 299,461 | - | ||||||
Lease liabilities | 32,167 | 38,725 | ||||||
Deferred revenue | 135,005 | 118,861 | ||||||
Total current liabilities | 1,719,911 | 1,358,792 | ||||||
Lease liabilities | 114,255 | 140,776 | ||||||
Long-term debt, net of unamortized debt issuance costs | 647,527 | 646,901 | ||||||
Other noncurrent liabilities | 582,988 | 632,681 | ||||||
Total Amdocs Limited Shareholders' equity | 3,292,021 | 3,429,453 | ||||||
Noncontrolling interests | 41,935 | 41,227 | ||||||
Total equity | 3,333,956 | 3,470,680 | ||||||
Total liabilities and equity | $ | 6,398,637 | $ | 6,249,830 | ||||
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)
| 2026 | 2025 | |||||||
Cash Flow from Operating Activities: | ||||||||
Net income | $ | 501,242 | $ | 567,769 | ||||
Reconciliation of net income to net cash provided by operating activities: | ||||||||
Depreciation, amortization and impairment | 210,357 | 195,435 | ||||||
Amortization of debt issuance cost | 626 | 608 | ||||||
Equity-based compensation expense | 105,063 | 104,864 | ||||||
Deferred income taxes | 35,497 | 20,291 | ||||||
Loss from short-term interest-bearing investments | - | 3,487 | ||||||
Net changes in operating assets and liabilities, net of amounts acquired: | ||||||||
Accounts receivable, net | (193,360 | ) | 79,606 | |||||
Prepaid expenses and other current assets | (9,656 | ) | (55,061 | ) | ||||
Other noncurrent assets | 33,247 | (15,445 | ) | |||||
Lease assets and liabilities, net | (2,459 | ) | 3,221 | |||||
Accounts payable, accrued expenses and accrued personnel | 61,013 | (77,041 | ) | |||||
Deferred revenue | 1,000 | 8,172 | ||||||
Income taxes payable, net | (2,335 | ) | (15,109 | ) | ||||
Other noncurrent liabilities | (67,512 | ) | (71,701 | ) | ||||
Net cash provided by operating activities | 672,723 | 749,096 | ||||||
Cash Flow from Investing Activities: | ||||||||
Purchase of property and equipment, net (a) | (110,528 | ) | (103,952 | ) | ||||
Proceeds from sale of short-term interest-bearing investments | - | 169,993 | ||||||
Net cash paid for business and intangible assets acquisitions | (218,644 | ) | (86,317 | ) | ||||
Net cash from equity investments and other | 14,101 | 18,215 | ||||||
Net cash used in investing activities | (315,071 | ) | (2,061 | ) | ||||
Cash Flow from Financing Activities: | ||||||||
Repurchase of shares | (510,508 | ) | (551,340 | ) | ||||
Proceeds from employee stock option exercises | 6,980 | 21,294 | ||||||
Payments of dividends | (233,691 | ) | (224,394 | ) | ||||
Distribution to noncontrolling interests | (3,113 | ) | (4,039 | ) | ||||
Borrowings under financing arrangements | 300,000 | - | ||||||
Payment of contingent consideration and deferred payment of business acquisitions | (45,270 | ) | (9,642 | ) | ||||
Net cash used in financing activities | (485,602 | ) | (768,121 | ) | ||||
Net decrease in cash and cash equivalents | (127,950 | ) | (21,086 | ) | ||||
Cash and cash equivalents at beginning of year | 324,999 | 346,085 | ||||||
Cash and cash equivalents at end of year | $ | 197,049 | $ | 324,999 | ||||
(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the three and nine months ended June 30, 2026 and 2025, respectively.
AMDOCS LIMITED
Supplementary Information
(In millions)
| Three months ended | ||||||||||||||||||||
| September 30, | June 30, | March 31, | December 31, | September 30, | ||||||||||||||||
| 2026 | 2026 | 2026 | 2025 | 2025 | ||||||||||||||||
North America | $ | 733.9 | $ | 748.1 | $ | 754.3 | $ | 764.7 | $ | 762.4 | ||||||||||
Europe | $ | 192.6 | 193.5 | 191.8 | 181.7 | 179.8 | ||||||||||||||
Rest of the World | 267.3 | 233.3 | 225.8 | 209.5 | 208.0 | |||||||||||||||
Total Revenue | $ | 1,193.8 | $ | 1,174.9 | $ | 1,172.0 | $ | 1,155.9 | $ | 1,150.2 | ||||||||||
| Three months ended | ||||||||||||||||||||
| September 30, | June 30, | March 31, | December 31, | September 30, | ||||||||||||||||
| 2026 | 2026 | 2026 | 2025 | 2025 | ||||||||||||||||
Managed Services Revenue | $ | 728 | $ | 791 | $ | 759 | $ | 746 | $ | 748 | ||||||||||
| As of | ||||||||||||||||||||
| September 30, | June 30, | March 31, | December 31, | September 30, | ||||||||||||||||
| 2026 | 2026 | 2026 | 2025 | 2025 | ||||||||||||||||
12-Month Backlog | $ | 3,500 | $ | 4,260 | $ | 4,280 | $ | 4,250 | $ | 4,190 | ||||||||||
SOURCE: Amdocs Management Limited
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Oct-26 | |
| Oct-08 | |
| Oct-07 | |
| Sep-03 | |
| Aug-19 | |
| Aug-06 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite